How a well-planned clinical trial budget can help prevent burning bridges
A poorly negotiated budget can cause friction between sponsors and clinical trial sites, which can lead to fractured working relationships.
By
Urtė Fultinavičiūtė
Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy.
Latest articles
All Articles
Pipeline Moves: Boehringer, Stealth BioTherapeutics likely to see clinical trial progress of ophthalmic assets scuppered
Clinical Trials Arena also reviews AstraZeneca's Phase I AZD-0466 cancer trial termination.
By
DCT and clinical trial diversity: glass ceiling persists, researchers say
While DCTs aim to reduce traditional recruitment barriers, there is still work to be done to ensure diversity among…
By
Should Covid-19 clinical trial plans still centre around EUAs?
In the event the FDA limits or shutters its EUA pathway, it would throw Covid-19 vaccine and drug development…
By
The E in ESG: how CROs aim to leave a positive ecological mark
Clinical Trials Arena reviews publicly available ESG reports to see how CROs are looking to make improvements to their…
By
AI benefits in patient identification and clinical trial recruitment has challenges in sight
AI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management…
By
Pfizer dominates social media during Covid-19
Social media buzz is in line with the pharma company’s consequential milestones and other notable events
ByPipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops
Praxis in essential tremor and Altamira in vertigo are also reviewed by Clinical Trials Arena
By
Pipeline Moves: Terminations of fatty liver, blood cancer, ophthalmology clinical trials cause further study chances to nosedive
Bristol Myers Squibb, GT Biopharma, and Gemini Therapeutics terminate early-phase trials of their respective assets.
By